Immatics NV (IMTX)

[FACT-MASTER]

Welcome to the board.

Very possible on both subject points and i agree 100% with your rationale.

The collaborations here are highly impressive: Bristol Myers Squibb / GSK / Genmap / Editas / MDACC

https://immatics.com/collaborations/

This could get very interesting quickly, daily dollar value of the stock trading has exploded lately. All signals looking good.

[Solarfuture]

Agree! 20 and more we'll see soon here. One rumor about a takeover we'll see much more....

[FACT-MASTER]

Daily volume rising dramatically.

Looking good here at IMTX!!

[FACT-MASTER]

IMTX News:

https://fintel.io/doc/sec-immatics-nv-1809196-6k-2022-august-23-19227-6314

The importance of CD4 T cells for the duration of responses has been demonstrated by Immatics in preclinical assays where IMA203CD8 showed enhanced potency and prolonged anti-tumor activity compared to IMA203 alone. These findings are in line with a growing body of literature from CD19 CAR-T cells in hematological cancers that suggest a relevant role of engineered CD4 T cells in maintaining durable anti-tumor responses over a long period. Immatics? proprietary lentiviral vector enables CD4 and CD8 T cells to be engineered with the PRAME-specific IMA203 TCR and a CD8?? construct. In the preclinical studies, this approach showed functional superiority over multiple other CD8 constructs in conjunction with the PRAME-specific IMA203 TCR. Immatics has successfully developed a proprietary 4-in-1 vector that includes both IMA203 TCR? and TCR? as well as CD8? and CD8? chains while maintaining a high transduction rate, circumventing the challenges associated with increasing the lentiviral vector payload.



The IMA203CD8 Phase 1b dose expansion cohort is expected to enroll up to 24 patients with different types of solid tumors across several clinical trial sites in the U.S. and in Germany. Following personalized manufacturing and lymphodepletion, patients will receive a single dose of IMA203CD8. Initially, 3 patients will be treated at a dose level 3 (DL3, up to 0.48 billion total transduced T cells per m? body surface area) before patient treatment at the provisional recommended Phase 2 dose, DL4 (up to 1.2 billion total transduced cells per m? body surface area). The primary objective of this Phase 1b cohort is to evaluate the safety profile of IMA203CD8. Secondary objectives include evaluating initial anti-tumor and biological activity.



The 2nd generation TCR-T IMA203CD8 is part of Immatics? strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME. This strategy includes three Phase 1b expansion cohorts, which have all been initiated during the first half of 2022 and build on the promising early clinical results during the company?s Phase 1a trial. Interim data showed a 50% objective response rate (8/16 patients) across several solid tumor indications including melanoma, head and neck cancer, uveal melanoma and synovial sarcoma.


o Cohort A ? IMA203 as monotherapy at the provisional, recommended Phase 2 dose (RP2D) plus exploration of a higher dose level DL5 (up to 4.7 billion transduced CD8 T cells per m? body surface area)


o Cohort B ? IMA203 in combination with an immune checkpoint inhibitor, Opdivo? (nivolumab)


o Cohort C ? IMA203CD8, a 2nd generation monotherapy in which IMA203 is co-transduced with a CD8 co-receptor



Each Phase 1b expansion cohort is designed to evaluate the observed objective response rate, demonstrate durability of response and provide the basis for entering registration trials. The next data readout for the IMA203 monotherapy cohort at RP2D is expected during 2H 2022 and an initial data readout for Cohort B and Cohort C is planned for YE2022.

[FACT-MASTER]

Good accumulation - after a bit of a miss on revenue Q2

[FACT-MASTER]

Nice day here at IMTX!!

Looking forward to the next quarterly update.

[FACT-MASTER]

$11.62 AH Close!!

Good news on the way!

[FACT-MASTER]

What's up Doc??

[FACT-MASTER]

$10.71 AH close!!

[FACT-MASTER]

AH - What's UP?

35,248 shares traded at 16:48

Something up?

[FACT-MASTER]

Patent Granted:

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5535&f=G&l=50&d=PTXT&p=111&S1=20220628&OS=20220628&RS=20220628

[FACT-MASTER]

Volume spike June 17/22 = 587,510 shares traded (approx. 3x daily average)

[FACT-MASTER]

IMTX 1Q/22:

https://ca.finance.yahoo.com/news/immatics-announces-first-quarter-2022-110500276.html

[FACT-MASTER]

Immatics/Bristol Myers Squibb news:

https://ca.finance.yahoo.com/news/immatics-bristol-myers-squibb-expand-105900170.html

[FACT-MASTER]

IMTX News:

https://ca.finance.yahoo.com/news/immatics-announces-first-patient-treated-110000197.html

[FACT-MASTER]

"Immatics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 17th, 2022 based off prior year's report dates."

https://www.marketbeat.com/stocks/NASDAQ/IMTX/earnings/

Immatics (NASDAQ:IMTX) Earnings Estimates
Quarter Q1 2022
Number of Estimates 2
Low Estimate $1.65
High Estimate $2.07
Average Estimate$1.86

[FACT-MASTER]

Looks like a volume anomaly (570k) just before close.

[Solarfuture]

Some life seems to come in here...

[make it happen]

It is lolol best of luck. Over ten years in the game make it up, down and side ways

[Sukhoi]

Yes its a bio all investors know the risk/reward, you sound like it's your first day trading

[ClayTrader]

* * $IMTX Video Chart 03-17-2021 * *

Link to Video - click here to watch the technical chart video

[make it happen]

Covered 2/3 for small loss like $200 bucks. Was up 15k. Was a mistake after seeing the vwap premarket and kept hitting locates. Thanks, you too. Hope had a solid day. Def churning but thinking near capped for the day

[crudeoil24]

Good luck bud!

[make it happen]

Most def got burnt on a little short. Congrats to the longs what a squeeze. Numbers are wild. Worth about a billion with no numbers.. Oh well. Got a few other shorts decent. Waiting on few industries to come to bottom consolidation and go long long again.

[crudeoil24]

> Folks makin huge bank on day trading IMTX.

[make it happen]

Definitely does! Needs capital. Especially when has phase 2. Then phase 3. Then FDA approval. Then much more & has a long way to go. Imho

[Sukhoi]

Numbers don't matter in bios

[make it happen]

All these numbers are facts and numbers don't lie...

[make it happen]

Strong arm emoji

[crudeoil24]

Already sold! It's all about day trading > makin bank! Some folks sit on the sidelines and complain about profits. Carpe Diem!

[make it happen]

Nice pop only phase 1... Has phase 2, phase 3 & FDA approval.

Has no cash, debt, less than a million assets, no revenues, negative cash flows, negative margins & so much more...

Book value per share $1.22

[make it happen]

Net Margin Growth -171.13%

EBITDA Margin -160.12%

Net Income After Extraordinaries -(35.34M)

Net Income Available to Common -(35.34M)

[crudeoil24]

Immatics Sees Positive Data for Cancer Treatment Trials
7:29 am ET March 17, 2021 (Dow Jones) Print

By Chris Wack


Immatics NV said it saw positive clinical data from the dose escalation cohorts of its ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach.

The biopharmaceutical company said the treatment of patients with ACTengine product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as well as tumor shrinkage observed in 8 out of 10 patients including one partial response.

Immatics said clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile.

The primary objectives of the Phase 1 studies are to study the safety profile of the ACTengine product candidates in patients with target-positive solid cancers and to determine the recommended Phase 2 dose. Secondary objectives include the assessment of T cell engraftment, persistence and infiltration into the tumor, and the assessment of objective tumor responses.

ACTengine product candidates were well tolerated. All adverse events were transient and manageable. No dose-limiting toxicities were observed in patients treated with IMA201 and IMA202. One patient receiving IMA203 at dose level 2 experienced a dose limiting toxicity as defined in the trial protocol. The reaction was transient and fully resolved within 48 hours after onset.

Immatics shares were up 12%, to $13, in premarket trading.

[make it happen]

Market Cap of $780 million vs assets of $0.93 assets. Very negative profits.

Book Value Per Share $1.22

Gross Profit (ttm) $-21.64M

Current Assets $0.93M

Free Cash Flow $-0.32M

Free Cash Flow per Share $-0.02

Operating Cash Flow per Share $-0.02

[jondoeuk]

IMA204 preclinical data update at CAR-TCR Digital Week https://investors.immatics.com/static-files/841a9c73-7782-4aab-a4ce-23eb2481a376

[Solarfuture]

Looks interesting

[Mktman2024]

An advanced new way to target solid tumors with T cells
See major alliances

https://immatics.com/